Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis

BACKGROUND: Stage IV non-small cell lung cancer (NSCLC) is associated with a five-year survival rate of around 1%. Treatment with Viscum album L. (VA) extracts has been shown to reduce chemotherapy (CTx)-related adverse events, decrease CTx dose reductions and improve quality of life in a number of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schad, Friedemann, Thronicke, Anja, Steele, Megan L., Merkle, Antje, Matthes, Burkhard, Grah, Christian, Matthes, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110500/
https://www.ncbi.nlm.nih.gov/pubmed/30148853
http://dx.doi.org/10.1371/journal.pone.0203058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110500/
https://www.ncbi.nlm.nih.gov/pubmed/30148853
http://dx.doi.org/10.1371/journal.pone.0203058

Ejemplares similares